NEW YORK CITY, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ:MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers […]
NEW YORK, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ:SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Simulations Plus and certain of its officers
NEW YORK CITY, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ:RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation ("Encompass" or the "Company") (NYSE:EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Encompass and certain of its officers and/or
NEW YORK, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have
Kellanova (NYSE: K) today announced that its Board of Directors declared a dividend of $0.58 per share on the common stock of Kellanova, payable on September 15, 2025, to shareowners of record at the close of business on is September 2, 2025. The ex-dividend date is September 2, 2025. This is the 403rd dividend that
NEW YORK, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ("RxSight" or the "Company") (NASDAQ:RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether RxSight and certain of its officers and/or directors have engaged in
NEW YORK CITY, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of WPP plc ("WPP" or the "Company") (NASDAQ:WPP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether WPP and certain of its officers and/or directors
NEW YORK CITY, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Funko, Inc. ("Funko" or the "Company") (NASDAQ:FNKO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Funko and certain of its officers and/or directors
NEW YORK, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ:EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Edgewise and certain of its officers and/or directors